Alliance for Pandemic Preparedness

March 4, 2021

Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19

Category:

Topic:

Keywords (Tags):

  • In a randomized clinical trial among patients with symptomatic, laboratory-confirmed SARS-CoV-2 infection (n=400), a 5-day course of ivermectin did not significantly improve the time to symptom resolution compared with placebo (10 vs 12 days, HR=1.07, 95%CI: 0.87-1.32). Fifteen (7.5%) patients in the ivermectin group versus 5 (2.5%) in the placebo group discontinued treatment due to an adverse event.

López-Medina et al. (Mar 4, 2021). Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19. JAMA. https://doi.org/10.1001/jama.2021.3071